儿童代谢功能障碍相关脂肪性肝病(MASLD):儿童肥胖时代日益增长的健康问题
本文为叙述性综述,总结儿童青少年MASLD的流行病学、病理生理、自然史和管理。普通人群患病率13%,肥胖儿童中47%,男性及某些种族更高。管理以生活方式调整为核心,药物治疗作用有限,维生素E、omega-3脂肪酸和GLP-1受体激动剂等正在临床试验中探索并显示阳性结果。
要点
- MASLD是儿童青少年最常见的慢性肝病,普通人群患病率13%,肥胖儿童中47%。
- 管理以生活方式调整为核心,包括平衡、控制热量的饮食(尤其是地中海饮食)和规律体育活动。
- 药物治疗作用仍有限,维生素E、omega-3脂肪酸和GLP-1受体激动剂等正在临床试验中探索并显示阳性结果。
核心结论
- MASLD是儿童青少年最常见的慢性肝病,与全球儿童肥胖率上升并行。
- 尽管对该病的理解已有显著进展,但在自然史、早期识别和年轻人群有效治疗选择方面仍存在重要缺口。
- 本综述旨在支持持续研究并促进更适合年龄的照护方法。
研究设计与样本
- 本文为叙述性综述,汇总当前关于儿童青少年MASLD的证据。
主要发现
- 普通人群患病率13%,肥胖儿童中47%,某些种族和男性中观察到的患病率更高。
- MASLD早期常无症状,但部分患者可进展为脂肪性肝炎、纤维化、肝硬化和肝衰竭。
- 病理生理涉及过量热量摄入、胰岛素抵抗和脂质代谢改变等多因素。
- PNPLA3、TM6SF2、GCKR、MBOAT7和HSD17B13等基因变异影响疾病易感性和严重程度,有些增加风险而另一些显示保护作用。
- 肠-肝轴通过增加肠道通透性和菌群失调等机制促进肝脏脂肪堆积和炎症。
关键数值与推荐
- 普通人群MASLD患病率为13%。
- 肥胖儿童中MASLD患病率为47%。
临床怎么用
- 管理以生活方式调整为核心,包括平衡、控制热量的饮食(尤其是地中海饮食)和规律体育活动。
- 体重减轻与组织学改善相关。
- 药物治疗在MASLD管理中的作用仍有限,维生素E、omega-3脂肪酸和GLP-1受体激动剂等干预正在临床试验中探索并显示阳性结果。
局限性
- 原文指出在自然史、早期识别和年轻人群有效治疗选择方面仍存在重要缺口。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously called non-alcoholic fatty liver disease, has emerged as the most common chronic liver disease in children and adolescents. This is happening in parallel to the global rise in paediatric obesity. Prevalence estimates are 13% in the general population and 47% among children with obesity, with higher rates observed in certain ethnic groups and in males. MASLD is often silent in early stages but may progress to steatohepatitis, fibrosis, cirrhosis and liver failure in a subset of patients. The pathophysiology of MASLD is multifactorial, involving excess calorie intake, insulin resistance and altered lipid metabolism. Genetic variants, particularly in PNPLA3 , TM6SF2, GCKR, MBOAT7 and HSD17B13 influence disease susceptibility and disease severity, with some increasing the risk while others exhibiting a protective effect. The gut-liver axis, through mechanisms like increased intestinal permeability and dysbiosis, also contributes to hepatic fat accumulation and inflammation. The natural history of MASLD in children is variable. Some children may remain in remission while others may progress to advanced liver disease. Management is centred on lifestyle modification. A balanced, calorie-controlled diet, particularly a Mediterranean diet, has been shown to be beneficial in children and adolescents with MASLD, along with regular physical activity. Weight loss has been associated with histological improvement. Role of pharmacotherapy remains limited in the management of MASLD. Interventions like vitamin E, omega-3 fatty acids and GLP-1 receptor agonists are being explored in clinical trials with positive results. This narrative review is timely and relevant, as the growing burden of MASLD in children and adolescents calls for greater awareness and updated knowledge among clinicians and researchers. Despite notable progress in understanding the condition, important gaps remain regarding its natural history, early identification, and effective therapeutic options in the younger population. By bringing together current evidence and highlighting these areas of uncertainty, this review aims to support ongoing research and inform more age-appropriate approaches to care.
引用
- BMJ Paediatrics Open:Paediatric metabolic dysfunction-associated steatotic liver disease (MASLD): a growing health concern in the age of childhood obesity
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。